FDA panel backs InterMune's pulmonary fibrosis drug Esbriet despite reservations
10 March 2010
Malini Guha
Please Login to read the full article.
10 March 2010
Malini Guha
malini.guha@informa.com
By a decisive 9-3 vote, the US
FDA's advisory committee on pulmonary drugs on March 9th recommended that the agency approve the new drug application (NDA) from
InterMune to market as a treatment its drug Esbriet (pirfenidone) to reduce the decline in lung function in patients with idiopathic pulmonary...
Please Login to read the full article.
RELATED CONTENT
NEWS
- InterMune prices Esbriet in Germany and Norway and raises $231m in equity and loans
- EU approves InterMune "blockbuster" Esbriet; may face challenge from BI's 1120
- Intermune's orphan Esbriet falls foul of Germany's benefit assessment
- Boehringer Ingelheim's IPF drug impresses despite non-significant data
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
